Table 3.
Characteristics of Patients who Died of Disease
| Age/Gender | Risk Stratum | Lesion Treated by RT | Other Lesions | Prior Treatments | Technique | Dose (Gy) | Fractions | Concurrent Treatment | Time to Death (months) |
|---|---|---|---|---|---|---|---|---|---|
| 23F | MS/RO+ | Pituitary | Liver, Lungs | 2-CDA | conventional | 18 | 10 | none | 114 |
| 67M | MS/RO− | Lymph Node, Nasopharynx | none | none | IMRT | 50.4 | 28 | VBL | 19 |
| 33F | MS/RO− | Thyroid | Skin | none | unknown | unknown | unknown | surgery, imatinib, MTX | 36 |
| 39M | MS/RO+ | Thyroid | Kidney, bone, pituitary, bone marrow, lungs, mediastinum, heart | VBL, MTX, 6-MPIMRT | 25.2 | 14 | surgery | 34 | |
| 61F | MS/RO− | Lymph Node | Skin | none | conventional | 50 | unknown | none | 29 |
MS: Multisystem; RO: risk organ; 2-CDA: cladribine; MTX: methotrexate; 6-MP: 6-mercaptopurine